Project Description

Dr. Timothy F. O'Neill, MD

Dr. Timothy F. O’Neill joined Los Alamitos Cardiovascular in 1997. Dr. O’Neill is board certified in internal medicine and cardiovascular disease.

Dr. Timothy F. O’Neill’s Curriculum Vitae

Click here to download as a PDF


Internal Medicine, Cardiology

Board Certifications

  • Certified in Cardiovascular Disease
    American Board of Internal Medicine
    1993 (Recertification 2009)
  • Certified in Internal Medicine
    American Board of Internal Medicine
  • National Board Parts I,II,III
    National Board of Medical Examiners
    1985 – 1988

Current Hospital Appointments

Work History

  • Los Alamitos Cardiovascular/Los Alamitos Internal Group, Inc.
    Los Alamitos, California
    February 1997 – Present
  • Heart Institute of the Desert
    Rancho Mirage, California
    October 1993 – February 1997


  • Pacemaker Fellowship
    Long Beach Memorial Medical Center
    Long Beach, California
    July 1992 – June 1993
  • Cardiology Fellowship
    University of California, Irvine Medical Center
    Irvine, California
    July 1990 – June 1993
  • Internal Medicine Residency
    University of California, Irvine Medical Center
    Irvine, California
    June 1987 – June 1990
  • University of New Mexico School of Medicine
    Doctor of Medicine Degree
    Albuquerque, New Mexico
    August 1983 – May 1987
  • Undergraduate Education
    Creighton University

    Omaha, Nebraska
    Bachelor of Arts Degree in History, Summa Cum Laude
    August 1979 – May 1983

Educational Honors and Awards

  • Outstanding Intern Commendation
    Veteran’s Administration Medical Center
    Long Beach, California
  • Four Superior Scholastic Achievement Awards
    Creighton University
    1980 – 1983
  • Graduated Summa Cum Laude
    Creighton University

Clinical Expertise

  • Non Invasive Cardiology; Echocardiography: TEE, Dobutamine, Stress Echo
  • Invasive Cardiology: Catherization, Permanent Pacemaker Implantation

Research Experience

  • AEGIS: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome.
    Sub-Investigator | 2019
    Sponsor: CSL Behring LLC
  • COVET : Comparison of Oral anticoagulants for extended Venous Thromboembolism (COVET). It is a randomized, open label, active comparator to determine whether the direct oral anticoagulant apixaban and rivaroxaban are safer than warfarin (fewer bleeding complications) and still as effective as warfarin (no increase in recurrent blood clots).
    Sub-Investigator | 2018 – Present
    Sponsor : Patient-Centered Outcomes Research Institute (PCORI)
  • NODE 301: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia.
    Sub-Investigator | 2019
    Sponsor: Milestone Pharmaceuticals Inc.
  • NODE 302: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (Extension of NODE-301).
    Sub-Investigator | 2019
    Sponsor: Milestone Pharmaceuticals Inc.
  • PARADISE MI: A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.
    Sub-Investigator | 2018 – Present
    Sponsor: Novartis
  • PEA-VALVE: Phono- and Electrocardiogram Assisted Detection of Valvular Disease. This is data collection of recorded heart sounds + ECGs using Eko Duo and Eko Core devices to further refine and validate algorithms using de-identified diagnosis confirmed by gold-standard echocardiograms.
    Sub-Investigator | 2018 – Present
    Sponsor: Eko Devices
  • GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
    Sub-Investigator | 2017 – Present
    Sponsor: Amgen
  • PROVE-HF: A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
    Sub-Investigator | 2017 – 2019
    Sponsor: Novartis
  • Barostim Therapy for Heart Failure (BeAT-HF): The Barostim Neo – Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
    Sub-Investigator | 2016 – Present
    Sponsor: CVRx, Inc.
  • MLHFQ Study: Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
    Sub-Investigator | 2016 – 2017
    Sponsor: Gilead/ICON
  • THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS – Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
    Sub-Investigator | 2015 – Present
    Sponsor: AstraZeneca
  • Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
    Sub-Investigator | 2015 – 2016
    Sponsor: Amgen, Evider
  • DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
    Sub-Investigator | 2013 – Present
    Sponsor: AstraZeneca
  • ODYSSEY EFC11570: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
    Sub-Investigator | 2013 – 2017
    Sponsor: Sanofi
  • SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.
    Sub-Investigator | 2013 – 2017
    Sponsor: Yale University School of Medicine/NIH
  • RivaroxAFL3003: An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
    Sub-Investigator | 2013 – 2014
    Sponsor:  Janssen Scientific Affairs/Johnson & Johnson
  • Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.
    Sub-Investigator | 2013
    Sponsor: Tasly Pharmaceuticals
  • Cardiovascular Inflammation Reduction Trial (CIRT): Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
    Sub-Investigator | 2013 – 2018
    Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
  • User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE-0159.
    Sub-Investigator | 2012
    Sponsor: Alere San Diego
  • Mission® PT Coagulation Monitoring System Clinical Study.
    Sub-Investigator | 2012
    Sponsor: ACON Laboratories, INC.
  • The “BRIDGE” Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
    Sub-Investigator | 2012 – 2015
    Sponsor: National Institutes of Health (NIH) – National Heart, Lung and Blood Institute (NHLBI)
  • GLORIA-AF 1160.129: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
    Sub-Investigator | 2012 – Present
    Sponsor: Boehringer Ingelheim
  • BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
    Sub-Investigator | 2010 – 2012
    Sponsor: St. Jude Medical Center
  • The PROMISE Trial: PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
    Sub-Investigator | 2010 – 2014
    Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
  • ORBIT-AF I and II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
    Sub-Investigator | 2010 – 2017
    Sponsor: Janssen Scientific Affairs, LLC
    Collaborator: Duke Clinical Research
    NCT01165710 & NCT01701817
  • RATE: Registry of Atrial Tachyarrhythmia/Atrial Fibrillation(AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
    Sub-Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
  • FREEDOM: A Frequent Optimization Study the Quick Opt ™ Method.
    Sub-Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
  • ENGAGE: Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation – Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE – AF TIMI – 48).
    Sub-Investigator | 2009 – 2015
    Sponsor: Daiichi Sankyo Pharma Development

Medical Licensure

California, 1989